MS and Demyelinating Disorders

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Over a 5-year treatment period, patients on ofatumumab, regardless of race or ethnicity, demonstrated significant reductions in neurofilament light and achieved consistent rates of NEDA-3.

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

Scott Newsome, DO, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine, provided clarity on the 1-year data of the OCARINA II study assessing subcutaneous ocrelizumab.

Here's some of what is coming soon to NeurologyLive® this week.

The International Journal of MS Care publishes the abstracts for the CMSC Annual Meeting, which is set to be held May 29-June 1, 2024, in Nashville, Tennessee.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]

A trio of clinicians from Cleveland Clinic provided perspectives on the advances in neurology seen at the 2024 AAN Annual Meeting, specifically focusing in on epilepsy, stroke, and multiple sclerosis.

The study showed durable improvements in VEP latency with bexarotene, suggesting long-term benefits from exposure to a remyelinating drug.

The associate professor of neurology at Harvard Medical School discussed how clinicians face the challenging decision with their patients in choosing between off-label and approved medications for NMOSD. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.

Sean Pittock, MD, director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024.

Labeling updates underscore the importance of using compatible autoinjectors with specific glatiramer acetate injection products to prevent medication errors.

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

A recent network analysis of clinical trials demonstrated that ravulizumab exhibited greater efficacy in preventing relapse in patients with NMOSD compared with other treatments.

In patients with relapsing-remitting MS who achieved NEDA under highly effective DMT, sNfL concentrations were low and stable, suggesting a potential role for sNfL for long-term monitoring of inflammatory disease activity.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cluster headache.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 10, 2024.

Catch up on any of the neurology news headlines you may have missed over the course of April 2024, compiled all into one place by the NeurologyLive® team.

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]